Genetically guided treatment for newly diagnosed peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing whether a treatment chosen based on your tumor's genetic makeup works better than a standard one for people newly diagnosed with peripheral T-cell lymphoma. The goal is to find a more personalized approach that targets your specific cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma (a type of lymphoma that affects certain white blood cells).
- A tumor sample (from a past biopsy or a new one) must be available for genetic testing.
- You must have a tumor that can be seen on a PET or CT scan.
- You should be able to care for yourself and be up and about (performance status of 0, 1, or 2).
- You cannot have certain other types of lymphoma, such as ALCL or skin lymphoma, or lymphoma that has spread to the brain or spinal cord.
- You must not have had another cancer (except for certain skin cancers or early cervical cancer), and you must not have HIV or an active hepatitis infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of four chemotherapy drugs for people with a type of lymphoma called peripheral T-cell lymphoma who have not had treatment before. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This study tests whether adding a drug called selinexor to a standard chemo-immunotherapy combination (called R-GDP) can help people whose large B-cell lymphoma has a TP53 gene change and has not responded to earlier treatment. The goal is to see if this combination helps control the lymphoma.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Peripheral T-cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.